Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY

4 abstracts

Abstract
Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first line therapy.
Org: Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, Mount Sinai Health System, New York, NY, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, Mount Sinai Health System, NY, NY, Mount Sinai Health System, NY, NY, Icahn School of Medicine at Mount Sinai, New York, NY, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY, NYU, New York, NY, NYU Grossman School of Medicine, Department of Population Health, Division of Biostatistics, New York, NY,
Abstract
Phase 1 results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) or gemcitabine (gem) in advanced solid tumors.
Org: University of Washington/Fred Hutchinson Cancer Research Center, University of California, San Francisco, Division of Endocrinology, San Francisco, CA, Sarah Cannon Research Institute at HealthONE, University of Michigan Rogel Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Minimal residual disease by circulating tumor DNA as a biomarker of recurrence free survival in resected high-risk melanoma patients treated with mRNA-4157/V940, a personalized cancer vaccine, and pembrolizumab.
Org: Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, Earle A. Chiles Research Institute, Portland, OR, California Pacific Medical Center Research Institute, San Francisco, CA, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, The Angeles Clinic and Research Institute, Los Angeles, CA,
Abstract
Phase 1b study of batiraxcept (AVB-S6-500, BT) plus gemcitabine (G) and nab-paclitaxel (NP) as first-line treatment (1L) for advanced pancreatic adenocarcinoma (PDAC).
Org: Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, Cleveland Clinic Taussig Cancer Instititute, Gabrail Cancer Center, Roswell Park Cancer Institute, Boca Raton Regional Hospital, Lynn Cancer Institute,